Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olpasiran Effects on Coronary Artery Plaque Burden in Stable ASCVD with Elevated Lipoprotein(a)
jRCT2051250217Phase 2Recruiting
- Sponsor
- Amgen
- Start
- Mar 2026
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in atherosclerotic disease, coronary arteriosclerosis and lipoprotein(a) hyperlipoproteinemia (Lp(a)) comparing Olpasiran with Placebo (2 arms). Primary endpoint: Change in non-calcified plaque (NCP) volume from baseline to Week 72. Started Mar 2026; status: recruiting.
02
Drugs
olpasiran
03
Conditions
atherosclerotic diseasecoronary arteriosclerosislipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on jRCT2051250217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250217.